Compare Cassava Sciences Inc (FLNA) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance

FLNA trades at $0.8168 with minimal daily movement (+0.13%). The stock shows bearish technical signals with negative moving averages but has beaten earnings expectations for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam enables Phase 2a epilepsy trials, providing potential catalyst. However, the company reports zero revenue, negative EBITDA of -$95.19M, and concerning cash flow trends with net cash outflow of -$33.07M in 2025.

While analyst consensus is strongly bullish (67% buy ratings), fundamental weaknesses including negative profitability metrics and cash burn present significant risks. The FDA approval provides near-term optimism for the epilepsy drug pipeline, but execution risk remains high given the company's financial position and lack of current revenue streams.

MSTU trades at $40.50, up 2.66% with a bearish technical signal from moving averages while oscillators remain neutral. The stock faces significant resistance at $41-$43 levels with support at $37-$35. Recent corporate actions include a 10:1 reverse stock split effective August 24, 2026, and a $0.29 dividend declaration for H2-2026.

The leveraged ETF structure presents both opportunity and risk - offering amplified exposure to MSTR but with daily rebalancing that can erode value during volatility. Key risks include the compounding effect of daily leverage and Bitcoin price sensitivity. Investors should monitor the underlying stock's fundamentals and Bitcoin market dynamics closely.